Chronic rhinosinusitis with nasal polyps presents complex diagnostic and therapeutic challenges for clinicians worldwide. Historically, medical literature has frequently conflated recurring polyps with inadequate symptom management. However, distinguishing true recurrence in CRSwNP from persistent uncontrolled disease is vital for selecting appropriate medical, surgical, or biologic interventions. A landmark scoping review synthesizes evidence across 44 clinical studies from 2012 to 2026. This comprehensive analysis resolves longstanding ambiguities between these related clinical entities. Consequently, otolaryngologists and respiratory specialists can now adopt precise terminology to guide both daily practice and clinical trials.

Conceptual Differences in Disease Trajectory and Disease Control

Historically, clinicians used recurrence and uncontrolled disease interchangeably because both conditions share identical measurement domains. Both states capture patient-reported symptom burden, objective endoscopic findings, and escalating medical requirements. However, the scoping review demonstrates that they reflect fundamentally different clinical dimensions. Recurrence fundamentally evaluates a longitudinal trajectory across time. Therefore, diagnosing recurrence demands prior objective evidence of clinical improvement or surgical remission. In contrast, uncontrolled disease evaluates current disease burden against established clinical benchmarks at a single point in time. Consequently, a patient can present with uncontrolled disease without ever achieving prior remission. For example, a patient with recalcitrant mucosal inflammation who never clears following primary therapy remains uncontrolled. Clinicians cannot classify this presentation as a recurrence because no disease-free baseline ever existed. Conversely, a patient might experience polyp recurrence after functional endoscopic sinus surgery while remaining well controlled on topical intranasal therapy. Therefore, conflating these distinct concepts obscures patient outcomes and compromises scientific comparability across international cohorts.

Defining Recurrence in CRSwNP Following Endoscopic Sinus Surgery

The scoping review identified that published definitions of recurrence in CRSwNP concentrate heavily on post-surgical follow-up. Historically, surgeons relied almost entirely on polyp regrowth identified during rigid nasal endoscopy. Some investigator groups defined recurrence strictly as polyp tissue crossing predefined anatomic landmarks, such as protruding beyond the middle turbinate. Other clinical trials established revision endoscopic sinus surgery as the operational threshold for recurrence. However, relying solely on revision surgery introduces substantial administrative bias. Varied healthcare access, differing surgeon thresholds, and personal patient reluctance directly skew revision rates. Consequently, modern consensus definitions endorse a multidimensional assessment framework. This paradigm requires documented clinical worsening following an established post-operative nadir. The nadir generally occurs one to three months post-surgery after full mucosal re-epithelialization. Worsening must encompass subjective symptom deterioration alongside objective endoscopic evidence of tissue inflammation or polyp reformation. By adopting strict temporal rules, specialists differentiate genuine disease relapse from surgical failure or incomplete clearance.

Operational Frameworks for Uncontrolled Disease Across Treatment Modalities

Unlike recurrence, the construct of uncontrolled disease applies universally across medical, surgical, and biologic therapy settings. Operational criteria assess whether current therapy sufficiently suppresses sinonasal inflammation and restores acceptable quality of life. Guidelines from the European Position Paper on Rhinosinusitis and Nasal Polyps classify disease status into controlled, partly controlled, or uncontrolled categories. This evaluation examines nasal obstruction, rhinorrhea, facial pain, olfactory loss, sleep impairment, and systemic steroid requirements. When patients display persistent symptoms or demand frequent rescue oral corticosteroids, clinicians classify them as uncontrolled. Importantly, this classification requires no prior historical comparator. It merely evaluates the current level of disease control against acceptable clinical standards. Furthermore, modern management pathways use uncontrolled disease as the mandatory trigger for therapy escalation. For instance, international guidelines require evidence of uncontrolled disease before initiating monoclonal antibody therapy against type 2 inflammatory mediators. Establishing uniform operational rules for disease control ensures that candidates receive targeted interventions safely and cost-effectively.

The Four-Pattern Conceptual Map for Precision Phenotyping

To reconcile longitudinal trajectories with cross-sectional assessments, the scoping review constructs an innovative four-pattern conceptual map. This matrix crosses disease trajectory with current level of disease control. The first pattern comprises concordant controlled status, where patients maintain stable disease without recurrence. The second pattern involves concordant uncontrolled status, where disease recurred and actively impairs daily quality of life. However, the true clinical value emerges within the two discordant quadrants. In the third pattern, patients experience persistent uncontrolled disease without recurrence. These individuals never achieved symptomatic or endoscopic control after primary intervention, demonstrating primary treatment refractoriness rather than relapse. The fourth pattern encompasses recurrence with maintained control. In this scenario, minimal polyp regrowth occurs endoscopically, yet symptoms remain absent and overall burden stays low. Recognising these discordant states prevents premature or aggressive therapeutic changes. Clinicians can maintain conservative therapy when control persists, while promptly escalating therapy for refractory cases.

Therapeutic Implications: Biologics, Surgery, and Outcome Reporting

Integrating trajectory and control into clinical decision-making fundamentally refines therapeutic selection. Clinicians frequently encounter patients who fail standard maintenance therapies, including high-volume saline rinses and intranasal corticosteroids. When evaluating these individuals, practitioners must analyze treatment response, duration of therapeutic benefit, and previous surgical quality. If a patient experiences rapid recurrence shortly after thorough surgery, intense type 2 inflammation typically drives the pathology. Consequently, adding targeted biologics—such as dupilumab, omalizumab, or mepolizumab—provides substantial benefit. Conversely, if persistent uncontrolled disease stems from residual anatomical obstruction or recalcitrant osteitis, targeted revision surgery may offer the most appropriate remedy. Standardized outcome reporting in clinical registries will prevent ambiguous trial results. Furthermore, rigorous distinction between disease remission, treatment failure, and disease escalation ensures accurate benchmarking. Ultimately, combining trajectory and control aligns clinical practice with personalized precision medicine.

Actionable Recommendations for Clinical Practice

Specialists can immediately implement several evidence-based recommendations to standardize patient monitoring and documentation:

• Establish a documented baseline nadir at one to three months following surgery or medical induction before assessing recurrence.
• Utilize validated patient-reported outcome measures, such as the Sino-Nasal Outcome Test, in combination with nasal endoscopy scores.
• Distinguish clearly between primary treatment refractoriness and true disease relapse in patient records.
• Assess disease control systematically at every clinical encounter using EPOS criteria before deciding on therapeutic escalation.
• Engage patients in shared decision-making, factoring individual symptom tolerance and co-existing asthma into management plans.

What is the primary difference between recurrence and uncontrolled disease in CRSwNP?

Recurrence represents a longitudinal worsening of disease after a documented period of clinical improvement or surgical remission. In contrast, uncontrolled disease represents a cross-sectional assessment of current symptom burden, inflammation, and medication needs. Uncontrolled status requires no prior improvement. Consequently, a patient who never achieved remission remains uncontrolled rather than recurrent, whereas a recurrent patient may temporarily retain adequate control.

Why should clinicians avoid defining recurrence solely by revision sinus surgery?

Defining recurrence solely through revision surgery introduces significant reporting bias into clinical records. Surgical revision rates depend heavily on regional healthcare access, individual surgeon philosophy, operating room availability, and personal patient reluctance. Many patients live with severe symptomatic polyp recurrence but decline or cannot afford re-operation. Therefore, using revision surgery drastically underestimates the true rate of disease recurrence in clinical practice.

How does the four-pattern conceptual map guide biologic therapy decisions?

The four-pattern conceptual map separates cross-sectional control from longitudinal trajectory to prevent inappropriate treatment escalation. Patients with recurrence who maintain good symptom control do not require aggressive biologic therapies. Conversely, individuals who display persistent uncontrolled disease despite adequate baseline surgery represent ideal candidates for targeted biologic therapies. The matrix ensures costly therapies target truly refractory, severely burdened individuals.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Martin-Jimenez D et al. Recurrence Versus Uncontrolled Disease in Chronic Rhinosinusitis with Nasal Polyps: A Scoping Review of Conceptual and Operational Definitions. Curr Allergy Asthma Rep. 2026 Nov 09. doi: undefined. PMID: 43002191.

Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.

Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps: definition and management. J Allergy Clin Immunol. 2021;147(1):29-36.